Bortezomib

Drug Profile

Bortezomib

Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Childrens Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Millennium; Millennium Pharmaceuticals; Singapore General Hospital; Takeda Oncology; University of Michigan Comprehensive Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma
  • Registered B cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Glioma; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I/II Waldenstrom's macroglobulinaemia
  • Phase I Hodgkin's disease; Malignant melanoma; Neuroblastoma
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Adenocarcinoma; Amyloid light-chain amyloidosis; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; T cell prolymphocytic leukaemia

Most Recent Events

  • 04 Aug 2017 Janssen plans a phase III trial for Multiple myeloma (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in China and Taiwan (NCT03234972)
  • 19 Jul 2017 Janssen Research & Development plans a phase III trial for Multiple myeloma (Combination therapy, First-line therapy or greater) in China, South Korea and Taiwan (SC) in October 2017 (NCT03217812)
  • 25 May 2017 Millenium Pharmaceuticals terminates a phase II trial due to discontinued funding source in Acute lymphoblastic leukaemia and Lymphoma (Combination therapy, Second-line therapy or greater, In adults, In adolescents, In children, In infants) in USA (IV) (NCT02535806)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top